Methoxy poly (ethylene glycol)- block -poly (glutamic acid)- graft -6-(2-nitroimidazole) hexyl amine nanoparticles for potential hypoxia-responsive delivery of doxorubicin

Journal of Biomaterials Science, Polymer Edition

Volumn 27, Issue 1, 2016, Pages 40-54

  Ahmad, Zaheer ^a,b   Lv, Shixian ^a   Tang, Zhaohui ^a   Shah, Afzal ^b   Chen, Xuesi ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

Doxorubicin; Drug delivery; Hypoxia responsive; Nitroimidazole; Tumor microenvironment

Indexed keywords

AMINO ACIDS; BIOCOMPATIBILITY; CELL CULTURE; CHEMOTHERAPY; ETHYLENE GLYCOL; FOURIER TRANSFORM INFRARED SPECTROSCOPY; MOTION PICTURE EXPERTS GROUP STANDARDS; NANOPARTICLES; POLYMERS; POLYOLS; TUMORS;

,HYPOXIA RESPONSIVE; DEGREE OF SUBSTITUTION; DOXORUBICIN; DRUG DELIVERY VEHICLES; METHOXYPOLYETHYLENE GLYCOL; NITROIMIDAZOLES; TUMOR MICROENVIRONMENT; ZETA POTENTIAL MEASUREMENTS;

POLYETHYLENE GLYCOLS;

6 (2 NITROIMIDAZOLE)HEXYL AMINE; CARBOXYL GROUP; COPOLYMER; DOXORUBICIN; IMIDAZOLE DERIVATIVE; METHOXY POLY(ETHYLENE GLYCOL); NANOCARRIER; POLYGLUTAMIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; METHOXY POLY(ETHYLENE GLYCOL)-BLOCK-POLY(GLUTAMIC ACID)-GRAFT-6-(2-NITROIMIDAZOLE) HEXYL AMINE; MICELLE; NANOPARTICLE; NITROIMIDAZOLE DERIVATIVE;

ARTICLE; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CELL HYPOXIA; CHEMICAL STRUCTURE; CONJUGATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MCF 7 CELL LINE; MICELLIZATION; NANOENCAPSULATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SYNTHESIS; ULTRAVIOLET SPECTROSCOPY; ZETA POTENTIAL; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANOXIA; BREAST NEOPLASMS; CELL SURVIVAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; METABOLISM; MICELLE; PHYSIOLOGY; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANOXIA; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MCF-7 CELLS; MICELLES; NANOPARTICLES; NITROIMIDAZOLES; POLYGLUTAMIC ACID; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TUMOR MICROENVIRONMENT;

EID: 84948717437     PISSN: 09205063     EISSN: 15685624     Source Type: Journal    
DOI: 10.1080/09205063.2015.1107707     Document Type: Article

References (42)

1. Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today. 2006;11:812-818.
2. Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412-2417.
3. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Delivery Rev. 2013;65:71-79.
4. Liang J, Wu W, Lai D, et al. Enhanced solubility and targeted delivery of curcumin by lipopeptide micelles. J. Biomater. Sci. Polym. Ed. 2015;26:369-383.
5. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Delivery Rev. 2012;64:246-255.
6. Wei H, Zhang X-Z, Chen W-Q, et al. Self-assembled thermosensitive micelles based on poly(Llactide-star block-N-isopropylacrylamide) for drug delivery. J. Biomed. Mater. Res. Part A. 2007;83A:980-989.
7. de Graaf AJ, dos Santos IIAP, Pieters EHE, et al. A micelle-shedding thermosensitive hydrogel as sustained release formulation. J. Controlled Release. 2012;162:582-590.
8. Zhang J, Jiang X, Zhang Y, et al. Facile fabrication of reversible core cross-linked micelles possessing thermosensitive swellability. Macromolecules. 2007;40:9125-9132.
9. Chen W, Meng F, Cheng R, et al. pH-sensitive degradable polymersomes for triggered release of anticancer drugs: A comparative study with micelles. J. Controlled Release. 2010;142:40-46.
10. Lavi G, Voronov E, Dinarello CA, et al. Sustained delivery of IL-1Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases. J. Controlled Release. 2007;123:123-130.
11. Song W, Li M, Tang Z, et al. Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers. Macromol. Biosci. 2012;12:1514-1523.
12. Zhang Y, Liu H, Hu J, et al. Synthesis and aggregation behavior of multi-responsive double hydrophilic ABC miktoarm star terpolymer. Macromol. Rapid Commun. 2009;30:941-947.
13. Rao J, Luo Z, Ge Z, et al. "Schizophrenic" micellization associated with coil-to-helix transitions based on polypeptide hybrid double hydrophilic rod-coil diblock copolymer. Biomacromolecules. 2007;8:3871-3878.
14. Hu J, Zhang G, Liu S. Enzyme-responsive polymeric assemblies, nanoparticles and hydrogels. Chem. Soc. Rev. 2012;41:5933-5949.
15. Li M, Tang Z, Sun H, et al. pH and reduction dual-responsive nanogel cross-linked by quaternization reaction for enhanced cellular internalization and intracellular drug delivery. Polym. Chem. 2013;4:1199-1207.
16. Thambi T, Deepagan VG, Yoon HY, et al. Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials. 2014;35:1735-1743.
17. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. National Cancer Inst. 2001;93:266-276.
18. Harris AL. HYPOXIA-a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2002;2: 38-47.
19. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer. 2004;4:437-447.
20. Takasawa M, Moustafa RR, Baron J-C. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. Stroke. 2008;39:1629-1637.
21. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer. 2011;11:393-410.
22. Ding J, Zhuang X, Xiao C, et al. Preparation of photo-cross-linked pH-responsive polypeptide nanogels as potential carriers for controlled drug delivery. J. Mater. Chem. 2011;21:11383-11391.
23. Rami M, Dubois L, Parvathaneni N-K, et al. Hypoxia-targeting carbonic anhydrase ix inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J. Med. Chem. 2013;56:8512-8520.
24. Hay MP, Hicks KO, Wang J. Hypoxia-directed drug strategies to target the tumor microenvironment. In: Constantinos K, Ester H, Amato G, editors. Tumor Microenvironment and Cellular Stress. New York: Springer; 2014. p. 111-145.
25. Yang Y, Pan D, Luo K, et al. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials. 2013;34:8430-8443.
26. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007;2:751-760.
27. Li L, Wang Y, Ji F, et al. Synthesis and characterization of dendritic star-shaped zwitterionic polymers as novel anticancer drug delivery carriers. J. Biomater. Sci. Polym. Ed. 2014;25:1641-1657.
28. Song W, Tang Z, Zhang D, et al. Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin. Biomaterials. 2014;35:3005-3014.
29. Song W, Tang Z, Li M, et al. Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects. Acta Biomater. 2014;10:1392-1402.
30. Lv S, Tang Z, Li M, et al. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials. 2014;35:6118-6129.
31. Li Q, Lv S, Tang Z, et al. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: Preparation, in vitro and in vivo evaluation. Int. J. Pharm. 2014;471:412-420.
32. Li M, Song W, Tang Z, et al. Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer. ACS Appl. Mater. Interfaces. 2013;5:1781-1792.
33. Yu H, Tang Z, Zhang D, et al. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy. J. Control Release. 2015;205: 89-97.
34. Yifei Li, Y H, Sun Hai, et al Cisplatin-loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) nanoparticlesas a potential chemotherapeutic agent against osteosarcoma. Chin. J. Polym. Sci. 2015;33:763-771.
35. Ahmad Z, Tang Z, Shah A, et al. Cisplatin loaded methoxy poly (ethylene glycol)-blockpoly (L-glutamic acid-co-L-phenylalanine) nanoparticles against human breast cancer cell. Macromol. Biosci. 2014;14:1337-1345.
36. Zhao L, Ding J, Xiao C, et al. Glucose-sensitive polypeptide micelles for self-regulated insulin release at physiological pH. J. Mater. Chem. 2012;22:12319-12328.
37. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009;100:572-579.
38. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Delivery Rev. 2011;63:184-192.
39. Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer. 2004;91:1775-1781.
40. Plummer R, Wilson RH, Calvert H, et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer. 2011;104:593-598.
41. Edwards DI. Nitroimidazole drugs-action and resistance mechanisms I. mechanism of action. J. Antimicrob. Chemother. 1993;31:9-20.
42. Carreau A, Hafny-Rahbi BE, Matejuk A, et al. Why is the partial oxygen pressure of human tissues a crucial parameter? small molecules and hypoxia. J. Cell. Mol. Med. 2011;15:1239-1253.